Aprilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor that selectively inhibits PDE4, increases intracellular cyclic adenosine monophosphate (cAMP) levels, and regulates inflammatory responses.

1. Drug name

Common name: Apremilast

Product Name: Otezla ®

2. Indications

Used to treat adult patients with active psoriatic arthritis.

3. Specifications and characteristics

30mg， Tablets.

4. Main components

The active ingredient is apremistat.

5. Usage and dosage

Patients with severe renal insufficiency: The recommended dose is 30mg once a day.

6. Dose adjustment

Renal insufficiency: For patients with severe renal insufficiency (CLcr<30mL/min), the dosage should be adjusted to 30mg once a day.

Liver dysfunction: No need to adjust dosage.

7. Medication precautions

Before/after meals: can be taken before or after meals.

Missed medication: Take it as soon as possible during the regular medication period. If it is close to the next medication time, skip the missed dose and take the next dose at the regular time. Do not take double the dose at once.

Vomiting: If vomiting occurs quickly after taking medication, the original dose should be taken again.

8. Medication for special populations

Pregnant women: Use only when potential benefits outweigh risks.

Breastfeeding women: Not recommended for use, apremistat can be secreted through mouse milk.

Children: The safety and efficacy of patients under 18 years old have not been determined.

Elderly patients: Patients aged 65 and above should use medication with caution, as their exposure to apremistat may be about 13% higher than that of younger patients.

9. Adverse reactions

The most common adverse reactions (incidence ≥ 5%) are diarrhea, nausea, and headache. About 10% of patients may experience a weight loss of 5-10% and require regular weight monitoring.

10. Contraindications

Patients who are known to be allergic to apremistat or any excipients in the formulation are prohibited from using it.

11. Drug interactions

Do not use in combination with potent CYP450 enzyme inducers (such as rifampicin, phenobarbital, carbamazepine, phenytoin), as they significantly reduce the blood concentration of apremilast, leading to loss of efficacy.

12. Storage method

Sealed and stored in an environment below 30 ° C (86 ° F).

Apremilastinformation